Scholarlink

<p>This clinical case describes the course of a&#xa0;woman with metastatic triple negative breast cancer involving the brain, lungs, and lymph nodes who was enrolled in the phase&#xa0;II clinical trial TUXEDO‑2 investigating datopotamab deruxtecan (Dato-DXd) for the treatment of active (newly diagnosed or progressing after prior local treatment) brain metastases. After six cycles of therapy, she discontinued the study to undergo neurosurgical resection followed by radiotherapy of a&#xa0;single progressing cerebellar metastasis causing compression of the fourth ventricle, while all other intra- and extracranial lesions demonstrated a&#xa0;significant response to Dato-DXd. The patient subsequently continued Dato-DXd treatment off-trial and remained on therapy for a&#xa0;total duration of 2.5&#xa0;years at the time of last follow-up.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Durable intracranial response to multidisciplinary treatment in triple-negative breast cancer: case report

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月2日

查看全文
  • Angelika M. Starzer,
  • Maximilian Marhold,
  • Rupert Bartsch

摘要

This clinical case describes the course of a woman with metastatic triple negative breast cancer involving the brain, lungs, and lymph nodes who was enrolled in the phase II clinical trial TUXEDO‑2 investigating datopotamab deruxtecan (Dato-DXd) for the treatment of active (newly diagnosed or progressing after prior local treatment) brain metastases. After six cycles of therapy, she discontinued the study to undergo neurosurgical resection followed by radiotherapy of a single progressing cerebellar metastasis causing compression of the fourth ventricle, while all other intra- and extracranial lesions demonstrated a significant response to Dato-DXd. The patient subsequently continued Dato-DXd treatment off-trial and remained on therapy for a total duration of 2.5 years at the time of last follow-up.